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New Consensus Criteria for GDM
Problem solved or a Pandora’s box?
F
oratleastagenerationtherehasbeen
a divergence of opinions about ges-
tational diabetes mellitus (GDM).
Ononehandwerethosewho,onthebasis
oflargelyobservationalstudiesinhumans
and extrapolation of animal data, felt that
women should be tested for GDM and
have their diagnosed GDM treated. On
the other hand, there were the “obskep-
tics” who felt that no signiﬁcant action
should be taken until evidence of beneﬁts
and risks was available. Clinicians of ei-
ther persuasion undoubtedly have found
developmentsoverthelastfewyearsmost
exciting.
In 2005, Crowther et al. (1) pub-
lished the results of the Australian Carbo-
hydrate Intolerance Study in Pregnant
Women (ACHOIS). For women diag-
nosed with GDM, the rate of prespeciﬁed
perinatal complications was lower for the
women randomized to the intervention
(treatment) group. In a recent publica-
tion, Landon et al. (2) found that women
with mild glucose intolerance who were
assigned to treatment had a signiﬁcant re-
duction in prespeciﬁed complications,
mainly related to fetal size.
Although universal testing for GDM
was not applied in either study, the ad-
vantages of treatment were clear. How-
ever, what was not clear was how the two
studies could be compared. Crowther et
al. used a 2-h plasma glucose test with a
75-g glucose load and the World Health
Organization (WHO) criteria designated
to diagnose impaired glucose tolerance in
a nonpregnant population (3). Landon et
al. used a 3-h 100-g glucose load and cri-
teria ultimately derived from the predic-
tion of future diabetes in the mother (4).
The use of these criteria, none of which
have been derived for pregnancy out-
comes, makes comparison of outcome
data problematic.
However, while these two treatment
trials were being conducted, another
study was underway speciﬁcally to deter-
mine the risks of adverse pregnancy out-
comes related to the maternal glucose
level. The Hyperglycemia and Adverse
Pregnancy Outcomes (HAPO) Study was
a large multicenter multinational blinded
study published in 2008 (5). This effec-
tively demonstrated a continuum of risk
for maternal glucose levels and adverse
pregnancy outcomes. The HAPO Study
used a 2-h 75-g glucose load with no pre-
liminary screening based on either risk
factors or a challenge test.
AfterthereleaseoftheHAPOStudy,a
group designated the International Asso-
ciation of Diabetes in Pregnancy Study
Groups (IADPSG) was created to formu-
late recommendations for glucose toler-
ance testing in pregnancy based on the
results of the HAPO Study, and these re-
sults appear in this issue of Diabetes Care
(6).
Given that a continuum of risk was
found in HAPO, the recommendations of
IADPSG are, of necessity, based on a con-
sensusaroundanarbitrarydecisionabout
odds ratios. That so many leading experts
in the ﬁeld from a wide range of countries
were able to meet and come to an agree-
ment is a credit to the perseverance of the
organizing committee, a reﬂection of the
strength of the database, and a desperate
desire for international uniformity.
However, the new criteria proposed
would diagnose 18% of all women in
pregnancy as having GDM, which is
about double the proportion of women
hitherto designated. Clearly the implica-
tions of this doubling will need serious
consideration.
The most obvious problems will re-
late to the health care costs of these addi-
tional diagnoses as well as possible
perceptions about the “medicalization” of
pregnancy. The inevitable increase in
costs may be a disincentive for some na-
tional health care systems to adopt a con-
sensus approach. It may also lead, for
pragmatic reasons, to the adoption of a
different odds ratio for risk stratiﬁcation
that may result in a lesser number of
women being diagnosed.
The majority of women diagnosed
with the IADPSG criteria are diagnosed
on the basis of glucose results, fasting and
at 1 h. A more convenient 1-h glucose
tolerance test may increase patient adher-
ence and compensate for the small num-
ber of additional cases identiﬁed by the
2-h glucose level. So far, no mention has
been made of consumer preferences.
The IADPSG has been concerned
with developing criteria based on preg-
nancy outcomes. Women identiﬁed will
presumably also be women at higher risk
of progressing to type 2 diabetes. What
maternal glucose criteria are associated
withadverseintrauterineprogrammingis
a question that only the future will
determine.
Currently, there is broad consensus
about the upper range for fasting and
postprandial glucose target levels for
treated women with GDM. The Interna-
tional Diabetes Federation (7), for exam-
ple, has recommended that a fasting
glucose 100 mg/dl (5.5 mmol/l)
should be one of the action points for
starting insulin or oral agents. How
should this be revised in light of the new
diagnostic criterion of a fasting glucose
92 mg/dl (5.1 mmol/l)?
Could the identiﬁcation of a greater
number of women at risk of an adverse
pregnancy outcome itself cause harm? It
is well documented that a diagnostic cat-
egory of GDM, irrespective of the glucose
control achieved, in some instances is
likely to result in increased interventions,
earlier delivery, an increased cesarean
section rate, and a higher number of ba-
bies being admitted to special care nurs-
eries.Couldtheserealhazardsoffsetsome
of the potential advantages?
The work of the IADPSG has been a
signiﬁcantcontributiontoourknowledge
and understanding of GDM. As always,
solutions of an immediate problem raise
questions for the future. “May you live in
interesting times” will certainly be the fu-
ture for GDM research and management.
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